Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to -$50.6 million.

  • Ani Pharmaceuticals' Retained Earnings rose 4353.72% to -$50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.6 million, marking a year-over-year increase of 4353.72%. This contributed to the annual value of -$100.3 million for FY2024, which is 2514.23% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Retained Earnings is -$50.6 million, which was up 4353.72% from -$76.9 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Retained Earnings peaked at -$5.0 million during Q1 2021, and registered a low of -$100.3 million during Q4 2024.
  • Over the past 5 years, Ani Pharmaceuticals' median Retained Earnings value was -$80.1 million (recorded in 2023), while the average stood at -$69.2 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first soared by 5695.1% in 2021, then tumbled by 125731.32% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Retained Earnings (Quarter) stood at -$47.8 million in 2021, then plummeted by 103.68% to -$97.3 million in 2022, then grew by 17.63% to -$80.1 million in 2023, then fell by 25.14% to -$100.3 million in 2024, then soared by 49.55% to -$50.6 million in 2025.
  • Its last three reported values are -$50.6 million in Q3 2025, -$76.9 million for Q2 2025, and -$85.0 million during Q1 2025.